4.7 Article

Impeding the combination of astrocytic ASCT2 and NLRP3 by talniflumate alleviates neuroinflammation in experimental models of Parkinson's disease

Journal

ACTA PHARMACEUTICA SINICA B
Volume 13, Issue 2, Pages 662-677

Publisher

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2022.07.021

Keywords

ASCT2; NLRP3; Astrocytes; Inflammation; Neurodegeneration; Drug screening; Talniflumate; Parkinson?s disease

Ask authors/readers for more resources

The study demonstrates the involvement of ASCT2 in the progression of Parkinson's disease, with high expression correlated with dyskinesia. It further shows that genetic ablation of astrocytic ASCT2 alleviates neuroinflammation and rescues dopaminergic neuron damage. The drug talniflumate, identified through virtual molecular screening, inhibits astrocytic inflammation and prevents degeneration of dopaminergic neurons in Parkinson's disease models.
Alanine-serine-cysteine transporter 2 (ASCT2) is reported to participate in the progression of tumors and metabolic diseases. It is also considered to play a crucial role in the glutamate-glutamine shuttle of neuroglial network. However, it remains unclear the involvement of ASCT2 in neurological diseases such as Parkinson's disease (PD). In this study, we demonstrated that high expression of ASCT2 in the plasma samples of PD patients and the midbrain of MPTP mouse models is positively correlated with dyskinesia. We further illustrated that ASCT2 expressed in astrocytes rather than neurons signifi-cantly upregulated in response to either MPP thorn or LPS/ATP challenge. Genetic ablation of astrocytic ASCT2 alleviated the neuroinflammation and rescued dopaminergic (DA) neuron damage in PD models in vitro and in vivo. Notably, the binding of ASCT2 to NLRP3 aggravates astrocytic inflammasome-triggered neuroinflammation. Then a panel of 2513 FDA-approved drugs were performed via virtual mo-lecular screening based on the target ASCT2 and we succeed in getting the drug talniflumate. It is vali-dated talniflumate impedes astrocytic inflammation and prevents degeneration of DA neurons in PD models. Collectively, these findings reveal the role of astrocytic ASCT2 in the pathogenesis of PD, broaden the therapeutic strategy and provide a promising candidate drug for PD treatment. 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available